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Abstract 
The present study investigates two commercially produced over-the-counter 
smokeless herbal mixtures (FDA approved), DIPSTOP™ and BACCOFF™, influence on 
subjective withdrawal symptoms during smokeless tobacco deprivation. Participants (n = 
19) were studied under BACCOFF™ X Water, BACCOFF™ X DIPSTOP™, 
DIPSTOP™ only, and Water only conditions, one condition per week. The order of the 
conditions was assigned using a Latin square methodology and participants were randomly 
assigned to each order. The Nicotine Abstinence Scale, Beck Depression Inventory, and 
State-Trait Anxiety Inventory were administered at baseline, 24-hour, and 48-hour 
deprivation for each condition. Within subject analysis of variances were conducted 
across all dependent measures. Results showed that BACCOFF™ significantly reduced 
symptoms that reflect DSM-IV criteria for nicotine withdrawal compared with other 
symptoms of withdrawal, including craving. Future research should explore the 
effectiveness of these substitutes in smokeless tobacco cessation. 
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Alternatives to Smokeless Tobacco: Documented Reductions in Withdrawal Patterns 
Over the past decade, smokeless tobacco use has increased by 38.4% in the United 
States, while use of other nicotine products have progressively decreased (USDA, 1993). 
Among the estimated 10 million American smokeless users, over one third of them are 
below the age of 21 (Consensus Conference, 1986). Moreover, the number of adolescent 
and younger smokeless users appears to be increasing {Hill, Harrell & McCormick, 1992, 
Simon, Sussman, Dent, Burton & Flay, 1993). Concerns about these estimates involve the 
known risks of developing of nicotine dependence at younger ages (Jaffe, 1990; West, 
1988), including the significant health problems associated with chronic smokeless 
tobacco use (Hoffmann, Adams, Lisk, Fisenne & Brunnemann, 1987; Hoffmann, 
Djordjevic, Fan, Glynn & Connolly, 1995). This increasing number of young individuals 
using smokeless tobacco necessitates further systematic exploration examining variables 
that facilitates smokeless tobacco cessation, such as possible substitutable reinforcers of 
this behavior. 
Within the framework of a reinforcement paradigm, the psychological and 
physiological cues associated with smokeless tobacco consumption strengthen the 
behaviors related to repeated smokeless tobacco use. Upon removal of these cues, a 
distinct cluster of reactive symptoms, known as nicotine withdrawal, is elicited 
(Hatsukami, Gust & Keenan, 1987). Withdrawal symptoms are viewed as the primary 
variable that prompts relapse (Hughes, 1993). However, the differentiation between 
psychological versus physiological (pharmacological) factors that influence the 
exacerbation of withdrawal symptoms is not well understood. Given that nicotine 
administration has a distinct pharmacological effect, most researchers have concentrated 
on examining the effectiveness of pharmacological adjuncts to isolate (Benowitz, 1988; 
Cooper & Clayton, 1994), mimic (Bradshaw, 1973; London, 1963), or block (Clarke, 
1991; Hughes, 1993) nicotinic effects and reduce withdrawal. Combined with cognitive-
behavioral therapy, these attempts have met with minimal success. 
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Behavioral economics theory posits that reduction of a targeted behavior may be 
accomplished with the simultaneous presentation of substitutable reinforcers, such as 
pharmacological adjuncts (Bickel, Hughes, Degrandpre, Higgins & Rizzuto, 1992). 
However, an adequate reduction of the original behavior constitutes the substitutable 
reinforcer to approximate the original behavior as close as possible (Hursh & Bauman, 
1987). For example, smokeless tobacco use have both behavioral (including smokeless 
tobacco topography) and pharmacological components. Thus, a suitable reinforced 
substitution should approximate both components before one might witness a reduction in 
the targeted behaviors. Theoretically, the lack of a behavioral substitute within smokeless 
tobacco cessation studies may have contributed to the reduced treatment efficacy 
documented in most studies. 
The present study was designed to provide evidence that is consistent with this 
behavioral economic model of nicotine use by testing the primary components of a 
commercial smokeless tobacco cessation package. This package contains two possible 
herbal alternative adjuncts to smokeless tobacco. One herbal mixture, BACCOFF™, 
approximates the behavioral, including topographical, components associated with 
smokeless tobacco use without the pharmacological effects of nicotine. The other herbal 
mixture, DIPSTOP™, produces peripheral nicotinic pharmacological properties. It is 
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suggested that the administration of these herbal preparations will substantially reduce the 
effects of withdrawal during deprivation. 
It is noteworthy to mention that this study does not directly evaluate the behavioral 
economic model of substitutable reinforcers because smokeless tobacco use is artificially 
stopped for the purpose of examining withdrawal symptoms. A direct evaluation of this 
model would document naturalistic reductions in smokeless tobacco use as a function of 
herbal administration. Nevertheless, an indirect evaluation of the behavioral economic 
model of nicotine administration focusing on etiological factors, such as withdrawal 
symptoms, supplies valuable information. The documentation of withdrawal suppression 
with herbal administration provides two important contributions. First, the suppression of 
withdrawal symptoms would implicate use of these herbal preparations as potential 
substitutable reinforcers within the framework of a smokeless tobacco cessation program, 
subsequently increasing treatment efficacy. Second, substituting herbal preparations for 
smokeless tobacco would significantly reduce the health risks involved with smokeless 
tobacco use. 
Health Risks 
Epidemiological studies have consistently shown a relationship between smokeless use 
and oral cancer (Council on Scientific Affairs, 1986; Hoffinan et al., 1987; 1995). The 
substance of nicotine is not, in itself carcinogenic, but this tobacco alkaloid is a precursor 
to a group of carcinogens called the tobacco-specific nitrosamines (Hoffinan & Hecht, 
1985). It is speculated that high concentrations of nitrosamine found in smokeless 
tobacco increase the rate of oral cancer among smokeless tobacco users. More 
specifically, two of these nitrosamines, N-nitrosamine 4-(methylnitrosamine)-1-(3-
6 
pyridyl)-1-butanone (NNK.) and N-nitrosonornicotine (NNN) have been shown to 
produce cancer of the nose, trachea, esophagus, and liver in animals (Consensus 
Conference, 1986; Hecht et al., 1986). Moist snuff contains 1.6 to 135 mg/kg ofNNN 
and .1 to 14 mg/kg ofNNK while US foods and beverages are allowed to contain no more 
than .01 mg/kg ofnitrosamine (Hoffmann et al., 1995). Furthermore, a recent study has 
demonstrated significantly higher concentrations of these nitrosamine in the three leading 
brands of moist snuff (i.e., Copenhagen, Skoal, Kodiak) sold in the United States 
compared to other brands, such as Hawkins and Skoal Bandits (Hoffmann et al., 1995). 
To date, no evidence has documented decreases of these deleterious concentrations in 
smokeless tobacco (Hoffmann et al., 1995). 
Models of Nicotine Dependence 
Learning Paradigm 
Pavlovian Conditioning. Pavlovian conditioning has been used to explain one 
component of nicotine dependence. Rose and Levin (1991) and Iwamoto, Fudala, 
Mundy, and Williamson (1987) contend that Pavlovian conditioning contributes to the 
repeated use of nicotine. Nicotine administration (UCS) produces psychological and 
physiological states (UCR) which are paired with neutral environmental stimuli (CS). 
Iwamoto et al. suggest that these conditioned neutral stimuli pervade environmentally 
(e.g., sitting in front of a computer) and/or psychologically (e.g., anxiety, anger) specific 
contexts. Rose and Levin purport that cues from nicotine or the nicotine apparatus, such 
as the texture of the nicotine in smokeless tobacco or the smokeless tobacco tin, may 
represent conditioned stimuli. Over time, repeated pairings between a neutral 
environmental stimuli and nicotine administration produce a conditioned response ( e.g., 
craving) that initiates and maintains drug-seeking behavior. 
Reinforcement. Classical reinforcement theory postulates that an individual forms 
associations between stimuli and their response to the stimuli. These associations 
strengthen or weaken the behaviors related to the response. In general, nicotine use, 
including smokeless tobacco use, appears to fit within this paradigm. The administration 
of nicotine is associated with an individual's response to the drug. This association 
strengthens the behaviors related to nicotine use (e.g., drug-seeking behaviors). 
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Rachlin, Battalio, Kagel, and Green ( 1981) suggest that classical reinforcement theory 
should consider the context of the reinforcing event and the choice of the individual to 
partake in nicotine related behaviors, as well. Theoretically, an individual chooses 
situations that will maximize reinforcement properties in an environment (Rachlin et al., 
1981 ). Nicotine possesses a multitude of positive and negative reinforcement properties 
(Jarvik, 1991). For example, abstinence during sleep resensitizes tolerance and elicits 
withdrawal symptoms in the morning (Benowitz, 1990). This phenomenon produces a 
euphoric (aroused) response from the first cigarette (chew) of the day (Benowitz, 1990). 
In this situation, nicotine use is strengthened from both positive (e.g., euphoria) and 
negative ( e.g., withdrawal) reinforcement. Similarly, sedation effects reinforce usage after 
a meal, and improvement on working memory and/or attention reinforces nicotine use 
during activities such as studying or working. Although there have been inconsistent 
findings in research examining the reinforcing properties of nicotine use (Dunne, 
MacDonald & Hartley, 1986), a majority of studies have provided evidence to warrant 
consideration (Golding, & Mangan, 1982a, 1982b; Peeke & Peeke, 1984; Rusted & 
Eaton-Williams, 1991). 
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It appears that nicotine use is strengthened by multiple situations. Classical 
reinforcement theory would conclude that this strengthened nicotine related behaviors 
demonstrate reinforcement. However, the complexity of this reinforcement is not as clear 
when conceptualizing nicotine dependence solely within this model. Rachlin et al. ( 1981) 
postulated that nicotine users are not influenced by all of the possible situations that 
strengthen nicotine-related behavior. Thus, an element of choice must be involved in the 
reinforcement of these behaviors Nicotine users may, in fact, maximize the overall 
reinforcement property of nicotine by choosing a combination of situations that provide 
the optimal strengthening of behaviors associated with an individual's pattern of nicotine 
consumption. 
Behavioral Economics 
Behavioral economic theory explains the relationship between nicotine use and the 
effort (cost) to obtain the substance. This theory applies reinforcement and conditioning 
principles to the process of nicotine dependence. Behavioral economics can equally 
interpret increases in nicotine usage in terms of the reinforcing qualities of the drug-
effects. Nicotine use is also strengthened from the interaction between desired drug-
effects and the efforts to obtain the substance. Moreover, behavioral economics delineates 
the importance of mimicking both conditioned and reinforced properties of nicotine during 
cessation protocols. 
This theory consists of four basic components: (1) demand law, (2) elasticity, (3) unit 
price, and ( 4) alternative reinforcing stimuli. The demand law states that drug 
consumption (demand or drug effect) decreases as the effort or cost to obtain the 
substance (response requirement) increases (Allison, 1979). For example, if new laws 
(response requirement) prohibited nicotine use (demand), nicotine consumption would 
decrease as the penalty for using the substance increases. 
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Elasticity refers to the degree of demand and response requirement (cost) fluctuations 
(DeGrandpre et al., 1992). A substance is considered elastic when drug use significantly 
changes in relationship to an increase in response requirement. For example, exacerbated 
health risks may reduce or eliminate nicotine use. However, when drug use changes only 
slightly with an increase in response requirement, the substance is considered inelastic. 
Individuals who continue using,nicotine after they are diagnosed with cancer exemplify 
inelasticity. 
Unit price refers to the interaction between the magnitude of the reinforcing property 
of a substance and the magnitude of the response requirement (Hursh, Raslear, Shurtleff, 
Bauman & Simmons, 1988). The unit price illustrates second-order properties of drug 
reinforcement. For example, as drug effects decrease with a stable response requirement, 
drug usage increases to stabilize the demand-response requirement relationship. This 
effect demonstrates the acquisition of tolerance. Conversely, as the response requirement 
increases ( e.g., withdrawal symptoms elicited from conditioned stimuli) with a stable drug-
effect, usage increases to counteract the withdrawal patterns. 
Alternative reinforcing stimuli refers to the ability of other stimuli (e.g., nicotine gum) 
to act as a substitute or compliment of the original reinforcing agent (e.g., smokeless 
tobacco). A substitutable relationship increases behaviors associated with other stimuli as 
the behavior associated with the original stimulus decreases (Bickel, Hughes, Degrandpre, 
Higgins & Rizzuto, 1992). The more similar an alternative reinforcer is to the original 
substance, the more effective the behavioral change. In other words, an alternative 
reinforcer that approximates the properties and effects of the original substance will be 
more effective at reduced the behaviors associated with the original substance (Hursh & 
Bauman, 1987). Conversely, complimentary relationships mimic the fluctuations of the 
original stimulus (Bickel et al., 1992). As the behaviors related to the original substance 
increases, the behaviors associated with the complimentary reinforcer increases as well. 
For example, coffee consumption (a compliment) will increase as nicotine use increases. 
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Theoretically, substitutes for nicotine use should possess similar properties associated 
with nicotine dependence. An adequate substitute elicits comparable responses from 
conditioned stimuli and strengthens behaviors associated with positive and negative 
reinforcing properties of nicotine. All else being equal, a substitutable reinforcer stabilizes 
the relationship between drug use and response requirement without administering the 
original drug. This stabilization suppresses negative reinforcing properties elicited from 
abstinence. 
Smokeless Tobacco Cessation 
Smokeless tobacco cessation studies have focused on self-directed intervention in a 
variety of settings (Glover, Wang & Glover, 1994; Stevens, Severson, Lichtenstein, Little 
& Leben, 1995; Williams, Arheart & Klesges, 1995). Self-directed interventions have also 
examined replacement treatments (Sinusas & Coroso, 1993; Stevens et al., 1995) and 
multiple baseline treatment protocols (Dilorenzo, Kern & Pieper, 1991). This research has 
demonstrated minimal abstinent rates ( approximately 20% ), which are less than the typical 
30% abstinent rate from smoking cessation programs (Carmody, 1990). Low abstinent 
rates inherently implies the entrenched behavioral patterns associated with smokeless 
tobacco use and higher level of dependency. 
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Prior to 1993, researchers had not studied replacement treatments within smokeless 
tobacco cessation programs (Sinusas & Coroso, 1993). Sinusas and Coroso were the first 
to study the effectiveness of nicotine gum with smokeless tobacco users. A 12-month 
follow-up study showed minimal abstinence maintenance. Stevens et al. (1995) employed 
mint leaf non-tobacco products, chewing gum, and toothpicks as substitutes for smokeless 
tobacco related behaviors within their cessation protocol. Although the substitutes were 
not directly evaluated, this study demonstrated a 33%, 12-month abstinence rate. 
It is evident that smokeless tobacco cessation and possible components to treatment 
have not thoroughly been investigated. Recently, studies have suggested that replacement 
treatments may be possible avenues to control smokeless tobacco withdrawal during 
cessation (Sinusas & Coroso, 1993; Stevens et al., 1995). Nevertheless, abstinent rates 
have been marginal and inconclusive at best. More systematic exploration of the 
effectiveness of smokeless tobacco substitutes to reduce withdrawal symptoms is 
necessary prior to planning new innovative treatment protocols that implement such 
substitutes. 
Nicotine Withdrawal 
The Diagnostic and Statistical Manual of Mental Disorders, 4th edition (DSM-IV; 
American Psychiatric Association, 1994) delineates withdrawal symptoms that consistently 
produce effects from nicotine abstinence. Individuals who meet DSM-IV criteria for 
nicotine withdrawal must experience four or more of the following symptoms or groups of 
symptoms during abstinence: (1) dysphoric or depressed mood; (2) insomnia; (3) 
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irritability, frustration, or anger; (4) anxiety; (5) difficulty concentrating; (6) restlessness; 
(7) decreased heart rate; and (8) increased appetite or weight gain (American Psychiatric 
Association, 1994). They must also report daily use for at least several weeks, exhibit 
withdrawal symptoms that cause clinically significant distress or impairment in daily 
functioning, and experience symptoms that are not better accounted for by a medical 
condition or other mental disorders. 
Craving, a withdrawal symptom excluded from DSM-IV, represents a motivational 
state that perpetuates drug-using behavior and precipitates relapse during abstinence ( 
Kozlowski & Wilkinson, 1987; Marlatt, 1985; West & Schneider, 1987). It has been 
posited that this motivational ( central) state subsumes both "physical" and "psychological" 
determinants (Ludwig, Wilkers & Stark, 1974; Kozlowski & Wilkinson, 1987; Tiffany & 
Drobes, 1991). Researchers have found it difficult to separate craving elicited from 
physical determinants, such as withdrawal symptoms (Shiffman, 1987), and psychological 
determinants, such as an intense desire for drug-seeking behavior {Rankin, Hodgson & 
Stockwell, 1979; Tiffany & Drobes, 1991). Craving was removed from the DSM-IV 
nicotine withdrawal criteria partially due to the difficulties in differentiating between 
psychological and physiological determinants (Hughes, 1996). 
There is ample evidence, however, to warrant the study of this concept with nicotine 
dependent individuals during abstinence. For instance, craving remains a prominent 
feature of nicotine abstinence (Glassman et al., 1984; Hughes & Hatsukami, 1986), and 
consistently predicts relapse (Killen et al., 1992; Marlatt, 1985). Moreover, research 
examining how craving interacts with withdrawal patterns is also needed. 
13 
Nicotine withdrawal research has historically focused on the abstinence effects of 
smokers (Hughes & Hatsukami, 1986; Hughes, Higgins & Hatsukami, 1990). In 
particular, deprivation studies have identified a host of withdrawal symptoms (e.g., 
anxiety, depression, irritability) related to smokers, usually beginning within 24-hours and 
peaking within 48-hours of deprivation (Hughes, Higgins & Hatsukami, 1990). 
Researchers typically have compared both the 24-hour and 48-hour deprivation periods to 
a baseline (pre-quit) period using self-report and physiological measurements (Hughes et 
al., 1990; Hughes & Hatsukami, 1986). 
There have been few studies addressing deprivation effects related to smokeless 
tobacco users. The overall results from these studies have demonstrated a similar 
response pattern to smokers, only qualitatively less intense (Hatsukami, Gust & Keenan, 
1987; Keenan, Hatsukami & Anton, 1989). A recent study comparing young college 
student smokeless tobacco user and smoker's withdrawal patterns exemplifies the 
consistency in withdrawal patterns between smokers and smokeless users (McChargue & 
Collins, 1998). Contrary to Hatsukami et al. and Keenan et al., however, McChargue and 
Collins found that smokeless users' withdrawal severity were proportional to smokers. 
Less intense smokeless tobacco withdrawal severity and comparable withdrawal 
patterns between smokers and smokeless users have led researchers to minimize the 
importance of smokeless tobacco withdrawal. The premise that both forms of nicotine 
administration elicit equivalent withdrawal patterns appeared to negate the importance of 
psychological ( e.g., conditioning) compared with physiological components of nicotine 
withdrawal. In essence, it was suggested that withdrawal symptoms are a function of the 
substance regardless of the mode of administration. Consequently, DSM-IV nicotine 
withdrawal criteria (American Psychiatric Association, 1994) delineate symptoms that 
support this hypothesis. It does not differentiate among different forms of nicotine use. 
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Recent literature on reinforcement properties of nicotine and Pavlovian conditioning 
effects provide evidence that supports the idea that withdrawal patterns may be a function 
of the nicotine administration method (e.g., chewing, smoking) and the environment. 
Conditioned stimuli (e.g., texture of tobacco, smokeless tobacco tin) are paired with both 
drug-effects and withdrawal symptoms. Furthermore, the multitude of situations that 
produce positive and negative reinforcement influence individuals to maximize the optimal 
reinforcement properties of nicotine. It is clear that smokeless users are able to use the 
substance in many settings that smokers are restricted from use due to the form of 
administration. For example, smokeless tobacco is easily used in sports and work areas 
that restrict smoking because of second-hand smoke issues. Thus, topographically 
conditioned cues (e.g., tin, texture, taste) unique to smokeless tobacco use may elicit 
differential withdrawal symptoms compared with smoking cues ( e.g. taste of cigarette, 
cigarette package). 
Smokeless Tobacco Topography 
Pavlovian conditioning and behavioral economics theories illustrate the importance of 
topographical specificity when investigating nicotine dependence and possible treatment 
issues. Theoretically, conditioned topography elicits biphasic responses. It either cues 
behaviors associated with nicotine use or activates withdrawal symptoms. 
Unlike a cocaine user's well defined and elaborate topographical routine, a smokeless 
tobacco user's routine appears more subtle and less involved, but equally as important to 
the smokeless user. Hatsukami, Keanan, and Anton (1988) outlined some topographical 
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features associated with smokeless tobacco users, such as mean number of tins per week, 
duration of smokeless tobacco use, and dips per day. It is suggested that other behavioral 
features (e.g., packing moist snuff with tongue), not yet empirically documented, may also 
contribute to the overall topographical conditioned effect. 
Hatsukami, Keenan, and Anton's (1988) produced the only empirical evidence 
detailing topographical features of smokeless tobacco. They reported that the results 
' 
demonstrated a potential contribution to dependence, but they did not speculate how these 
topographic features related to classical conditioning. For example, Hatsukami et al. 
documented that the mean number of dips/day was 6.3 (SD = 2.2). The average male user 
was 20.7 years (SD= 1.9)~ the mean age of onset was 16.2 (SD= 2.3)~ and the average 
duration of smokeless tobacco use was 5.2 years (SD= 2.4). Over 5.2 years, a male 
smokeless user will have taken 11,924.64 dips of tobacco (6.3 dips/day X 7 day/wk X 52 
wk/yr. X 5.2 years of usage). Moreover, a male smokeless tobacco user will spend 
approximately 39.9 (SD= 16.5) minutes per dip of tobacco (Hatsukami et al. 1988). 
Adding the amount of time performing this behavior into the equation, an average dipper 
will spend approximately 765,538.95 hours using smokeless tobacco within 5.2 years. 
Considering the magnitude of these estimates, the behaviors associated with smokeless 
tobacco use should be well conditioned after 5.2 years and should play an important role 
in cessation. 
Researchers have not yet documented topographical behaviors associated with 
smokeless use. It is suggested that after many years of use, the behaviors associate with 
this administration become well-ingrained conditioned stimuli. For example, the 
proverbial ring formed on the back pocket of jeans from years of placing tins in the 
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pocket, carrying a tin of tobacco at all times, snapping the tin to pack the tobacco before 
use, and placing the dip in a specific location along the gums appear to be conditioned 
pairings. This speculation is consistent with research examining placed-conditioning of 
nicotine (Fudala & Iwamoto, 1986; Fudala, Teoh & Iwamoto, 1985). Placed-conditioning 
research has demonstrated the importance of context-specific stimuli (Fudala et al., 1985). 
Although researchers commonly purport environmental stimuli, such as a specific location 
in a maze with animals and a specific situation or activity (e.g., at a computer, studying) 
with humans, conditioned contextual stimuli may be reduced to the specific behaviors 
associated with the use of smokeless tobacco. 
Similarly, the behaviors associated with dipping duration also may become conditioned 
stimuli, especially after the average user's 765,538.95 hours of use over 5.2 years. For 
example, the location of the dip placement may become conditioned during use. Research 
has shown that older dippers absorb nicotine at a quicker rate than novice dippers 
(Russell, Jarvis, Devitt & Feyerabend, 1981; Russell, Jarvis & Feyerabend, 1980). This 
provides some evidence that the mouth adapts to the placement of the tobacco, thus 
conditioning a specific location. Furthermore, the packing behavior of the tobacco during 
dipping may be similarly conditioned. Anecdotally, this is evinced by the ritualistic placing 
of the tongue in that specific location during abstinence or without smokeless tobacco in 
the mouth. Additionally, the amount of saliva produced during smokeless use is also 
conditioned. Although no research has quantified the amount of saliva produced during 
use or elicited from cues, its function is speculated to be similar to findings in other 
classical Pavlovian conditioning studies (Russell et al., 1981). Other possible conditioned 
stimuli during dipping are the taste arid texture of the tobacco. Similar to the other 
conditioned stimuli, tactile and taste stimuli are significantly paired after numerous 
learning trials. 
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This evidence supports the idea that smokeless tobacco use consists of well ingrained 
behavioral and sensory conditioned responses. The large amount of conditioned pairings 
from numerous topographical features exemplify the importance of developing techniques 
that control for conditioning effects during cessation. 
One possible alternative for extinguishing these behaviors is through viable substitutes 
that address these issues. A behavioral economic paradigm provides the theoretical 
foundation for such a substitute. According to behavioral economics, individuals should 
increase the use of a substitute as the target behavior (e.g., smokeless tobacco use) 
decreases. Furthermore, potential behavioral substitutes should closely approximate the 
target behaviors before it is effective (Hursh & Bauman, 1987). Therefore, a substitute 
that looks, feels, and tastes like smokeless tobacco and is packaged in a similar container 
void of nicotine, theoretically, would be a viable substitute for the topographical features 
of smokeless tobacco. 
Pharmacological Therapies 
Behavioral economics theory provides a theoretical basis for pharmacological 
therapies. Alternative drug substitutes and/or alternative forms of nicotine administration 
have played a substantial role in the reduction or elimination of withdrawal patterns during 
abstinence. Jarvik and Henninfield (1988) have discussed multiple pharmacological 
approaches to facilitate cessation or deprivation. Traditionally, there have been four 
specific avenues applied to nicotine dependence: (1) nicotine replacement, (2) withdrawal 
relief, (3) aversive nicotine intake, (4) and nicotine receptor blockage. Current literature 
18 
has focused on replacement approaches using nicotine polacrilex (gum), transdermal 
systems (patch), and nasal sprays (to a lesser degree). However, over-the-counter 
commercial products have manufactured other supplements ( e.g., Nikoban) which contain 
substances that attempt to alleviate withdrawal symptoms. Although previous research 
has found mixed results concerning effectiveness of supplement substances, such as 
lobeline (the primary ingredient in Nikoban), they still appear to play a part in smoking 
cessation. Other pharmacotherapies will be further discussed later in this section. 
Nicotine Replacement Therapies 
Nicotine polacrilex (Nicotine Gum). Nicotine gum is typically administered to 
smokers with 2 to 4 mg of nicotine per piece of gum (Leischow, Sachs, Hensen & 
Bostrom, 1995) and individuals chew 10-15 pieces of gum per day (Benowitz, 1988). 
Although some research has demonstrated a decrease in cigarette smoker's withdrawal 
symptoms with individuals averaging 8.6 pieces per day (West, Hajek & Belcher, 1989), 
Benowitz suggests that fewer than 10 pieces may not ensure an adequate amount of 
nicotine for noticeable dose effects, resulting in therapeutic failure. 
It is suggested that treatment should last no more than three months with the gradual 
reduction of nicotine (Benowitz, 1988). Once placed on nicotine gum, triturating the 
dosage does not exacerbate withdrawal symptoms. Research has shown. a decrease in 
cigarette smoker's withdrawal symptoms while progressively reducing the dosage over a 
four week period (West et al., 1989). Furthermore, prolonged treatment may create 
dependence to the nicotine gum. Studies have shown substantial increases in withdrawal 
symptoms with treatments lasting more than three months (West and Russell, 1985; 
Hughes, Hatsukami & Skoog, 1986). Whereas, Hatsukami, Huber, Callies, and Skoog 
(1993) demonstrated minimal withdrawal symptoms after 1 and 3 months of usage. 
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Other factors to consider when administering nicotine gum are properly instructing 
clients on how to use the gum, combining treatment with psychotherapy, and potential 
side effects. First, research has demonstrated the importance of proper instructions. 
Instructions have been shown to influence craving reduction (Hughes, Gulliver, Amori, 
Mireault & Fenwick, 1989) and improper usage has been shown to decrease the 
effectiveness of the gum (Lee & D' Alonzo, 1993). For example, drinking coffee and 
carbonated beverages while using the gum significantly diminishes the amount of nicotine 
absorbed (Lee & D' Alonzo, 1993). Furthermore, the gum is not chewed like bubble gum, 
it is gently chewed periodically to elicit an effect (similar to puffing a cigarette) and then 
parked between the teeth to ensure maximum absorption (Miller & Cocores, 1991). 
Moreover, swallowed nicotine in saliva is altered before entering the blood stream, 
minimizing the amount of nicotine absorbed in the system ( Cooper & Clayton, 1994; 
Miller & Cocores, 1991). Second, research has shown that combining behavior therapy 
with nicotine gum is more effective than behavior therapy alone or nicotine gum treatment 
alone (H1,1ghes, 1991). Lastly, common side effects include a sore throat or mouth, 
hiccups, tired jaws, nausea or other gastrointestinal symptoms, palpitations, and 
occasionally, mouth ulcers (Benowitz, 1988). 
Transdermal Systems Therapy (Nicotine Patch). There are 16-hour and 24-hour 
transdermal patches available, usually consisting of 15 to 24 mg of nicotine per patch 
(Cooper & Clayton, 1994). Commercially manufactured transdermal systems (i.e., 
Nicoderm, Habitrol, Nicotrol, and Prostep) suggest an average of 14 weeks of transdermal 
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treatment for smokers including gradual reduction of dosage (Cooper & Clayton, 1994). 
A meta-analysis conducted by Fiore, Stevens, Smith, Jorenby, and Baker (1994), however, 
demonstrated that treatment of smokers beyond 8 weeks including dose reduction did not 
appear to increase efficacy. Furthermore, developing drug dependence from the patch has 
not been thoroughly investigated. Therefore, it is recommended that treatment duration 
should be planned and monitored carefully. 
The patch has certain advantages over nicotine polacrilex. First, there is no risk of 
minimizing the administration of nicotine because nicotine is absorbed directly through the 
skin into the blood (Glover & Glover, 1994). Second, individuals using the patch 
experience fewer adverse physiological effects than cigarettes (Muller et al., 1990) and 
fewer side effects than nicotine gum (Rose, Herskovic, Trilling & Jarvik, 1985). The only 
noticeable side effect is skin irritation. However, rotating the application site will 
minimize the skin irritation (Cooper & Clayton, 1994). Other systemic effects, such as 
nausea, vomiting, sweating, dizziness, abdominal pain, chills, and headaches were seen as 
frequently with placebo groups (Cooper & Clayton, 1994). Third, the patch has been 
shown to be significantly more effective than a placebo regardless of adjunctive 
approaches, such as combining the patch with counseling (Fiore et al., 1994). In addition, 
research has demonstrated significant decreases in spontaneous smoking (Pickworth, 
Bunker & Henningfield, 1994 ), reduced withdrawal and depressive symptoms (Levin et 
al., 1994), and a doubled rate of continuous abstinence up to one year (Stapleton et al., 
1995). 
Nicotine Nasal Sprays and Aerosols. Nicotine nasal sprays and aerosols were 
originated in hopes to increase dose accuracy and absorption rates. Absorption rates with 
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nicotine polacrilex and transdermal nicotine systems are clearly more gradual with a 
correspondingly slower uptake to the brain (McDonald & Olson, 1994). However, 
nicotine aerosol effects have been shown to be similar to cigarette effects, eliciting a sharp 
rise in plasma nicotine followed by a slower decline (Pomerleau, Flessland, Pomerleau & 
Hariharan, 1992). Furthermore, as a supplement for smoking cessation, nasal sprays have 
been shown to decrease nicotine concentrations after 4 weeks (Sutherland, Russell, 
Stapleton, Feyerabend & Femo, 1992). The side effects experienced from nasal sprays, 
such as lightheadedness and slight dizziness (Sutherland et al., 1992), combined with 
reports of nasal aerosols being somewhat aversive (Pomerleau et al., 1992), warrant 
further research. There are few studies investigating the effectiveness of nicotine nasal 
delivery devices, dependence issues, and safety issues. Therefore, more research is needed 
before implemented into cessation programs. 
Withdrawal Relief Therapy 
Lobeline Therapy. Lobeline is a derivative of the lobelia, or Indian Tobacco, plant 
which mimics peripheral effects of nicotine (Dorsey, 1963). Although studies have shown 
aversive side effects, such as dizziness, nausea, and vomiting; appearing 15-30 minutes 
after administration (Ejrup, 1960), London (1963) demonstrated that .5 mg oflobeline 
sulfate in a cherry flavored pastille reduced the side effects oflobeline and suppressed 
craving for nicotine. Typically, lobeline is administered in .5 mg capulates mixed with an 
antacid (Bradshaw, 1973) or flavored pastilles (London, 1963). Individuals taking 
lobeline derivatives are instructed to take 3 to 4 capulates a day (Davison & Rosen, 1972). 
The length of administration ranges from one week to eight weeks. However, the length 
of administration has not been shown to be an important variable in the improvement 
treatment efficacy (Davison & Rosen, 1972). 
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Research demonstrating the effectiveness of lobeline to reduce smoking behavior has 
been mixed (Berstein, 1969; Bradshaw, 1973; Schuster, Lucchesi & Emley, 1979); there 
are no studies that have examined lobeline with smokeless tobacco users. Although 
reviews of lobeline have stated that the few controlled studies have not consistently shown 
lobeline to be more effective than a placebo, recent evidence has shown that sublingual 
lobeline sulfate significantly reduced cigarette smoker's withdrawal symptoms (Schneider 
et al., 1996). Despite the lack of consistent findings showing lobeline as effective nicotine 
deterrent, over-the-counter lobeline products are still available. Bantron is sold as a 
mixture of2 mg oflobeline sulfate and 1200 mg of antacid, and Nikoban is presented in .5 
mg capsules oflobeline and a flavored inactive base (Davison & Rosen, 1972). It is 
suggested that lobeline has not been thoroughly researched. Future studies examining the 
effectiveness for reducing withdrawal symptoms in conjunction with behavior therapy is 
warranted. 
Other Therapies. Clonidine, an antihypertensive medication, and Scopolamine, a 
medication for motion sickness, have been suggested as potential supplements (Miller & 
Cocores, 1991). In both cases, these drugs have been shown to reduce withdrawal 
symptoms (Corores, Sinaikin & Gold, 1989; Glassman, Jackson & Walsh, 1984). 
Furthermore, both substances are administered through transcutaneous patches for 3 to 4 
weeks, gradually triturating the doses (Miller & Cocores, 1991). It is important to note 
that the research concerning both clonidine and scopolamine is scanty. Therefore, the 
effectiveness of these drugs are unclear. 
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Several antidepressant and antianxiety medications have also been studied for their 
effectiveness as a smoking deterrent (Robbins, 1993). This line of research is relatively 
new and the results of a few studies have not elicited conclusive evidence supporting the 
use of antidepressants or antianxiety medications (Glassman, Jackson, Walsh & Roose, 
1984; Robbins, 1993). 
Aversive Nicotine Intake 
Silver Acetate. Silver acetate is available without prescription. Individuals are 
instructed to take 2.5 mg flavored lozenges every 4 hours for 3 weeks (Miller & Cocores, 
1991). The flavored lozenges produce an aversive taste in the mouth after the first puff of 
a cigarette (Miller & Cocores, 1991). To date, few controlled studies have been conducted 
(Malcolm, 1986; Rosenberg, 1977). Therefore, the effectiveness of this product is not 
clear. 
Nicotine Receptor Blockage 
Mecamylamine. The purpose of mecamylamine is to facilitate the pharmacological 
extinction of smoking behavior (Clarke, 1991). This substance increases smoking 
behavior while decreasing the reinforcing effects of nicotine (Hughes, 1993). Withdrawal 
symptoms have not been noted after the removal of mecamylamine. Hughes hypothesizes 
that the diminished withdrawal results because mecamylamine does not occupy nicotinic 
receptor sites. It simply blocks these receptor sites, preventing nicotine from affecting the 
organism. Prohibitive side effects (e.g., signs of ganglion blockade have caused 
participants to prematurely leave studies), however, warrant further research in this area 
(Clarke, 1991; Hughes, 1993). 
BACCOFF™ and DIPSTOP™ 
BACCOFF™ AND DIPSTOP™ are two commercially produced over-the-counter 
(FDA approved) herbal mixtures made specifically to combat smokeless tobacco 
dependence. The products were designed to alleviate the aversive effects of withdrawal 
during cessation. Theoretically, BACCOFF™ and DIPSTOP™ should produce similar 
topographical and pharmacological nicotinic responses to smokeless tobacco use. The 
lack of empirical evidence showing that both products effectively change smokeless 
tobacco behaviors warrants systematic exploration of components that may mediate this 
response ( e.g., withdrawal). 
24 
The DIPSTOP™ product has not been empirically studied. Its primary herb, lobeline, 
reliably mimics nicotinic effects in human and animal studies (Stolerman, 1990) and has 
helped prevent significant withdrawal symptoms during tobacco deprivation (Schneider et 
al., 1996). Research has primarily found lobeline to be ineffective at reducing smoking 
behavior (Berstein, 1969; Bradshaw, 1973; Schuster, Lucchesi & Emley, 1979). It was 
speculated that the ineffective results were possibly influenced by the disparate absorption 
rates between lobeline and cigarettes (Schuster et al., 1979). The absorption oflobeline is 
a gradual process which plateaus with continuous use (Stolerman, 1990). This pattern 
appears to be closer to smokeless tobacco absorption rates than cigarette absorption rates. 
According to behavioral economics, effective substitutes should closely approximate the 
original substance. Therefore, studies demonstrating similar nicotinic effects and 
absorption rates provide evidence that lobeline may be more appropriately employed with 
smokeless users rather than cigarette smokers. 
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Typically, research has not provided empirical evidence documenting lobeline effects 
on withdrawal patterns with cigarette smokers or smokeless users. However, recent 
research, emphasizing withdrawal reduction, has found that sublingual lobeline sulfate 
significantly reduces cigarette smoker's withdrawal symptoms (Schneider et al., 1996). 
These promising findings need to be replicated and extended to a smokeless tobacco 
population. 
BACCOFF™ is a commercially produced herbal mixture that has no nicotinic 
properties. It is administered ad lib similar to moist snuff products. There has been only 
one empirical study examining the similarities between BACCOFF™ and smokeless 
tobacco. Researchers found that BACCOFF™ produced similar olfactory, tactile, and 
taste responses to smokeless tobacco (Coffey & Lombardo, 1996). These findings 
suggest that BACCOFF™ may help control for topographical components (e.g., 
conditioned stimuli) of nicotine dependence. 
Goals of the Current Study 
Purpose 
The present study will investigate 24-hour and 48-hour deprivation effects during the 
administration of two alternative smokeless tobacco reinforcers (DIPSTOP™ and 
BACCOFF™). Four groups were constructed for the purpose of this study: BACCOFF™ 
+ Water, BACCOFF™ + DIPSTOP™, DIPSTOP™ only, and Water only. Water was 
used as a placebo to reduce potential expectancy effects from DIPSTOP™ administration. 
However, it was not feasible to employ a placebo for the BACCOFF™ condition. The 
groups will help differentiate deprivation effects associated with topographical features 
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(BACCOFF™) compared with physiological features (DIPSTOP™) of the alternative 
reinforcers. 
In general, the elimination or minimization of nicotine withdrawal during abstinence 
has been viewed as an important component in the treatment of nicotine dependence. 
Previous research has shown that withdrawal latency and magnitude (severity) 
qualitatively contribute to our understanding of the differences among withdrawal 
symptoms (McChargue & Collins, 1998). For example, McChargue and Collins showed 
the smokeless tobacco users withdrawal symptoms consistent with DSM-IV criteria 
showed significant elevations during 24-hour deprivation (short latency) compared with 
craving and other withdrawal symptoms, but did not show this difference in 48-hour 
deprivation. Their findings suggest that withdrawal symptoms consistent with DSM-IV 
criteria may be more amenable to deprivation effects compared with other signs and 
symptoms of withdrawal. Therefore, it was deemed necessary to evaluate 24-hour and 
48-hour deprivation compared with a baseline period. These data points will help 
elucidate differential latency and magnitude deprivation effects during product 
administration. 
These substitutable reinforcers theoretically possess entrenched topographical stimuli 
and physiological responses similar to smokeless tobacco. The purpose ofBACCOFF™ is 
to approximate topographically conditioned stimuli as DIPSTOP™ elicits similar systemic 
effects to smokeless tobacco. Overall, the administration of the products diminishes 
negatively reinforcing withdrawal symptoms while simultaneously controlling conditioned 
stimuli and positively reinforcing physiological effects. The purpose of the study 
exemplifies how conditioned stimuli, positive reinforcement, and negative reinforcement 
influence nicotine dependence. This complex interaction between conditioning and 
reinforcing variables associated with nicotine dependence demonstrates the need for 
comprehensive treatments. 
Hypotheses 
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It is predicted that BACCOFF™ administration during 24 hour and 48 hour 
deprivation will significantly reduce craving, DSM-IV withdrawal, total withdrawal, state 
anxiety, and depression scores compared to 24 and 48 hour deprivation without 
BACCOFF™ or DIPSTOP™ administration. The suppression of withdrawal symptoms 
associated with the administration of topographical variables will provide evidence to 
suggest that variables other than physiological responses (e.g., nicotine patch) may play a 
significant role in the development and maintenance of nicotine dependence. 
DIPSTOP™ administration during 24 and 48 hour deprivation is also expected to 
reduce craving, DSM-IV withdrawal, total withdrawal, state anxiety, and depression 
scores compared to 24 and 48 hour deprivation without DIPSTOP™ or BACCOFF™ 
administration. Documented reductions will reflect the effectiveness of an agonist to 
control withdrawal symptoms and will provide support for the utilization of non-nicotine 
treatments for smokeless tobacco cessation. Little is know about the pharmacological 
treatment of smokeless tobacco. This evidence may help validate and foster further 
research. 
Furthermore, the administration of BACCO FF™ and DIPSTOP™ is predicted to 
significantly reduce craving, DSM-IV withdrawal, total withdrawal, state anxiety, and 
depression scores during 24 hour and 48 hours deprivation compared to 24 and 48 hour 
BACCOFF™ x water, DIPSTOP™ only, and water only conditions. This evidence will 
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strongly reflect the importance of controlling conditioned stimuli, positive reinforcement, 
and negative reinforcement properties of smokeless tobacco. Moreover, this data will help 
us to differentiate between psychological and physiological components to smokeless 
tobacco consumption and direct our effort toward refining current treatment protocols. 
Method 
Participants 
Male undergraduate students (n=18) were recruited from undergraduate introductory 
psychology courses (PSYCH 1113) at Oklahoma State University and were given extra 
credit in their psychology classes as compensation for their participation. A research 
questionnaire (See Appendix A) was administered during their respective classes to assess 
for potential participants .. A lottery for $100. 00 was also conducted at the end of each 
semester. Participants completing the protocol were eligible for the lottery as an extra 
incentive. Although the lottery was an added incentive, participants received some 
incentive for their participation~ All participants received extra credit. 
Participants who reported at least two consecutive years of smokeless tobacco use 
without the use of any other nicotine product, was currently using 1 Yi tins/week, were 
over the age of 18, and scored above a 6.5 on the Smokeless Tobacco Dependence Scale 
were included in the project. Two participants were excluded from the study for repeated 
failure to abstain from nicotine products during the deprivation days. Participants had a 
mean age of 19.81 (SD= 1.87) years. The Smokeless Tobacco Dependence 
Questionnaire scores (M = 7.94, SD= 3.0) were higher than the cutoff mean score of6.5 
found in previous research (Boyle, Jensen, Hatsukami & Severson, 1995). Participants 
reported more than 2 years of continuous smokeless tobacco usage without currently 
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using any other form of nicotine products or attempting to quit or cut down on smokeless 
tobacco. These data suggest that the participants' dependency to smokeless tobacco was 
equivalent to participants in other withdrawal studies (Boyle et al., 1995; McChargue & 
Collins, 1998). See Table 1 for more detail demographics from the Smokeless Tobacco 
Dependence Questionnaire. 
Materials 
Saliva Samples. Saliva was collected to facilitate abstinence compliance. Individuals 
were informed that cotinine levels were collected and analyzed to assess systemic nicotine 
levels. No physiological or pharmacological indices, however, were derived from the 
samples. Saliva was stored in 16 X 100mm Pyrex cultured screw cap test tubes. All 
samples were placed in a freezer and discarded at the end of the study. Latex gloves were 
worn during all phases involving the handling of saliva samples. 
Alveolar Carbon Monoxide Monitor. Alveolar carbon monoxide (COa) was taken. to 
facilitate deprivation compliance and to assess for other forms of tobacco use. Carbon 
monoxide levels are an effective measure of smoking behavior, but cannot identify 
smokeless tobacco use. Participant COa samples were obtained using a Vitalograph 
BreathCOa monitor (Model 29.700). COa levels of8 ppm indicate significant carbon 
monoxide ratings, which may be caused by smoking. Individuals possessing COa levels of 
8 or higher were considered using nicotine products. 
Herbal Products. Two commercial herbal products were used in this study; 
BACCOFF™ and DIPSTOP™ (Ralston Inc., Selma, AL). BACCOFF™ is an herbal tea 
leaf product that has been shown to approximate salivary, olfactory, tactile, and taste 
responses elicited from a variety of commercial smokeless tobacco products (Coffey & 
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Lombardo, 1996). The ingredients contained in this product include tea leaves, natural 
and artificial flavors, glycerin, and sodium benzoate. The BACCOFF™ product was 
administered in a tin similar to smokeless tobacco moist snuff products. This method of 
administration approximates moist snuff usage, which allowed participants to use the 
product at the same frequency and amount as his original moist snuff product. For the 
purpose of this study, wintergreen and straight flavored BACCOFF™ were given to Skoal 
and Copenhagen moist snuff users, respectively. 
DIPSTOP™ was developed to produce systemic effects that approximate peripheral 
physiological nicotinic responses. Systemic effects were activated by the products primary 
ingredient lobeline, a nicotinic agonist (Stolerman, 1990). Other active ingredients within 
the DIPSTOP™ liquid drops are valerian root, wild lettuce, dandelion root, scullcap, 
borage, yerba mansa root, red clover blossom, chamomile flower, African cayenne, 
distilled water, and 35% natural glycerine by volume. Participants were instructed to 
ingest the substance four times per day through liquid drops regularly placed in a drink. 
Placebo. Water was placed in DIPSTOP™ containers to act as a placebo for the liquid 
drops. Participants and experimenters were blind to the substance in the liquid drop 
containers. No placebo was used for the BACCOFF™ product. 
Beck Depression Inventory (BDI). The BDI was designed to assess the severity of 
depression symptomatology (Beck & Steer, 1987). This scale consists of 21 items in a 
Likert-scale format ranging from Oto 4. Scoring categories are 0-9 (normal range), 10-15 
(mild depression), 15-20 (mild-moderate depression), 20-29 (moderate-severe 
depression), and 30-63 (severe depression). The BDI is also indicative of adjustment 
difficulties among college student (Gotlib, 1984; Tanaka-Matsumi & Kemeoka, 1986). 
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Researchers found that changes in BDI scores paralleled changes in the clinical levels 
of depression, indicating a consistent relationship between BDI scores and the patients 
clinical state (Stehouwer, 1985). The reliability figures were consistently above r = .90 (12 
< .001). Bumberry, Oliver, and McClure also found concurrent validity between the 
inventory and psychiatric ratings using university students, r = .77 (12 < .01). 
State-Trait Anxiety Inventory, Form Y (STAI). The STAI (Speilberger, Gorsuch, 
Lushene, Vagg & Jacobs, 1983) contains one scale measuring state anxiety and another 
scale assessing trait anxiety. The STAI-State consists of 20items designed to assess acute 
(state) anxiety levels. The ST AI-Trait consists of 20 items designed to evaluate chronic 
(trait) anxiety levels. Items are rated on a 4 point Likert-type scale (1-4), and total scores 
range from 20 to 80, with higher scores indicative of more anxiety. STAI-Trait scores 
were not used for this study. Internal consistency of the state-anxiety scale, as indexed by 
coefficient alpha, ranges from .86 to .95 (Chaplin, 1984). In addition, validity correlation 
coefficients tend to be . 70 and higher (Speilberger et al., 1983). 
Smokeless Tobacco Dependence Questionnaire (SMTDO). The SMTDQ (Boyle, 
Jensen, Hatsukami & Severson, 1995) is a 10 item self-report measure designed to 
measure aspects of smokeless tobacco use which correspond with dependence. This scale 
is a modified version of the Fagerstrom Tolerance Questionnaire (FTQ; Fagerstrom & 
Schneider, 1989) with added questions that reflect the unique characteristics of smokeless 
tobacco behavior and consumption. No cutoff scores were reported for this measure. 
However, Boyle, Jensen, Hatsukami, and Severson documented that the mean total score 
of 6.75 (SD= 1.76) was significantly correlated with cotinine levels (r = .47). 
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Nicotine Abstinence Scale (NAS). The NAS is a modified version of the Withdrawal 
Symptom Checklist (Hughes & Hatsukami, 1986) that was designed specifically for this 
study (See Appendix B). It consists of30 items in a Likert-scale format (0-none; I-mild; 
2-moderate; 3-severe) assessing both state and general withdrawal patterns. This study 
only utilized the state scale to assess across 48-hour deprivation conditions. The NAS is 
designed to produce Craving, DSM-IV withdrawal, and total withdrawal scores. To date, 
this scale has no reliability or validity data. 
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The DSM-IV score is obtained by taking the sum of participants' responses to items 3, 
4, 5, 11, 12, and 15. The highest score among DSM-IV grouped criteria, represented in 
items 2, 13, or 14, is also added to the DSM-IV score. Item 1 is evaluated separately to 
compare craving effects on overall withdrawal. The total withdrawal score is the sum of 
all of the items on the NAS. This score accounts for the overall withdrawal severity of the 
nicotine user. 
Procedure 
Latin square counterbalancing approach. Participants were placed in four conditions, 
BACCOFF™ X Water, DIPSTOP™ only, BACCOFF™ X DIPSTOP™, and Water only. 
These conditions were systematically ordered to reduce the probability of order and 
sequence effects. A Latin square design was used to ensure that the presentation of the 
orders was represented equally among all participants during each week of the protocol. 
The problem with a completely balanced Latin square design is that the number of groups 
and participants required may be prohibitive (Kazdin, 1992). Thus, the approach taken 
has inherent limitations. For example, conducting a completely balanced Latin square 
design was not feasible. 
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Given that BACCOFF™ is administered with a liquid drop (DIPSTOP™ or Water) 
twice for each participant, the first order of the conditions (represented at the beginning of 
this section) was organized to minimize potential sequence effects by the potential 
consecutive presentation ofBACCOFF™. In this initial order, the first and third weeks 
were slotted for BACCOFF™ administration with liquid drops and the liquid drop only 
administration were placed in the second and fourth weeks. The exact placement of each 
BACCOFF™ + liquid drop and liquid drop only conditions were randomly chosen. 
Consecutive orders were organized so that each condition would be represented an equal 
number of times during each week. The Latin square design used in this study is 
illustrated in Appendix C. 
Random assignment and procedure overview. The conditions were ordered using a 
Latin square design described above and assigned a number from 1 to 16. Numbers were 
drawn from a box and undergraduate assistants who were not involved in the protocol 
randomly assigned orders associated with the numbers to participants. Graduate 
researchers were blind to the DIPSTOP™ and Water components. All conditions entailed 
participants to attend three assessment periods (0 hours, 24 hours, and 48 hours) starting 
Monday and ending Wednesday for four consecutive weeks, one condition per week. 
Participants experienced all four conditions across the four weeks. Assessments were 
conducted the same time each day for all conditions. A summary of the experimental 
procedure is illustrated in Appendix D. 
0 hour assessment. Informed consent was obtained from all participants and the 
SMTDQ was administered during the initial 0-hour assessment period. Participants were 
given a disposable cup and a paper towel, and instructed to use their preferred moist snuff 
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for ten minutes. Following the using period, individuals were instructed to expectorate 
into a test tube. Carbon monoxide measures were then obtained using the COa monitor. 
A graduate researcher administered the BDI, STAI, and NAS to establish a baseline score 
for each scale. After the baseline assessment, individuals were instructed to abstain from 
any form of nicotine use for two days and to return the following day. Furthermore, 
participants were instructed to use a products assigned to that condition ad lib for the two-
day abstinence period. Graduate researchers also informed participants that "the products 
may or may not help during abstinence." 
24 hour assessment. Graduate researchers recorded the number of times individuals 
used the product (See Appendix E) and inquired on the participant's ability to abstain. 
Saliva and COa measures were collected. BDI, ST AI, and NAS self-report measures 
were also administered. Participants were instructed to continue abstinence and using the 
supplied products for another twenty-four hours. 
48 hour assessment. During the third assessment day, participants followed the same 
procedure as the 24-hour assessment period. After the last self-report measure was taken, 
any remaining products were given to the graduate researcher. Participants were 
encouraged to return to their regular nicotine use until the beginning of the next 
assessment week. This recidivism re-established baseline levels of nicotine use for each 
assessment week. 
At the end of the last assessment week, all participants were debriefed (See Appendix 
F) and given further information about the BACCOFF™ and DIPSTOP™ products. Each 
completed participant's name and phone number was then placed into ajar for the 
$100.00 lottery at the end of the semester. 
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Design and Statistical Approach 
A 2 X 2 X 3 factorial design reflects three independent within subject variables, 
BACCOFF™ (BACCOFF™ vs. No BACCOFF™), DIPSTOP™ (DIPSTOP™ vs. Water) 
and Time (0 hr., 24 hr.; 48 hr.). One-tailed repeated measure analysis of variances 
(ANOV As) were conducted on each of the dependent variables. The dependent variables 
included NAS DSM-IV withdrawal scores, NAS Total withdrawal scores, NAS Craving 
scores, BDI scores, and STAI-State scores. A total of five ANOVAs were conducted, 
one for each dependent variable. The ANOV As analyzed main effects for the independent 
variables ofBACCOFF™, DIPSTOP™, and Time. Interaction effects were also tested 
across the three independent variables, which produced four different comparisons. The 
interaction comparisons included BACCOFF™ x DIP STOP™, BACCOFF™ x Time, 
DIPS TOP x Time, and BACCOFF™ x DIPSTOP™ x Time. Post-hoc simple effect tests 
were used to differentiate significant interactions. Significant differences within the simple 
effects were followed up with Tukey's Honestly Significant Differences tests, at the .05 
alpha level. 
Results 
Power Analysis 
Power was calculated prior to the data collection phase of this study using the effect 
size from a previous research examining a similar population (McChargue & Collins, 
1998). An estimate sample size of 16 participants was equivalent to a beta of .95 at the 
.05 alpha level. This estimate dictated the sample sized used for this study. Post analysis 
of the actual power for this study showed a beta of .90 at the .05 alpha level. This post 
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analysis confirmed that the sample size for this study significantly reduces the probability 
of making a Type 1 error (rejecting the null hypothesis when it is true). 
Descriptive COa Levels and Product Frequency Data 
Deprivation compliance and product administration are vital to the outcome of the 
study. Compliance alveolar measures demonstrated that smokeless tobacco users were 
within the COa cutoff of 8 ppm during deprivation periods. Table 2 illustrates mean COa 
levels. Participants also reported adequate BACCOFF™, DIPSTOP™, and water self-
administration during deprivation as evidenced by endorsed frequency records. These 
findings suggest that the independent variables were effectively manipulated. This data is 
represented in Tables 3, 4, and 5, respectively. 
Order Effects 
A 2 (Time) by 4 (Order) ANOVA was conducted on the dependent variables (i.e., 
craving, total withdrawal, and DSM-IV withdrawal scores) that showed significant effects. 
The within subject independent variable was the repeated measure of time (0 hr., 24-hr., 
and 48-hr.). The order that the conditions (BACCOFF™ + DIPSTOP™, BACCOFF™ + 
Water, DIPSTOP™, and Water) were administered served as a between subject 
independent variable for this analysis. Craving, total withdrawal, and DSM-IV withdrawal 
scores showed no significant order effects as a function of time, E(3 ,12) = 3.27, .99, and 
.65, ns, respectively. These findings suggest that order effects had no influenced on the 
data. 
NAS DSM-IV Withdrawal Scores 
A 2 BACCOFF™ (BACCOFF™ vs. no BACCOFF™) X 2 DIPSTOP™ 
(DIPSTOP™ vs. water) X 3 TIME (0-hr., 24-hr., and 48-hr.) repeated measures ANOVA 
37 
was conducted on the NAS DSM-IV withdrawal scores. A significant time main effect 
was observed for withdrawal symptoms consistent with DSM-IV criteria, E(2, 30) = 4.40, 
n < .01. As seen in Figure 1, post hoc tests indicated that participants significantly 
increased in withdrawal from O hour (M = 2.53, SD= 2.89) deprivation compared to 24 
hour (M = 3.96, SD= 2.61) and 48 hour (M = 3.74, SD= 2.70) deprivation. 
BACCOFF™ and DIPSTOP™ main effects were not significant, Es(l, 15) = .91 and 1.31, 
fil.. respectively. 
Analyses testing the interaction among BACCOFF™, DIPSTOP™, and Time 
conditions showed a significant interaction between BACCOFF™ X Time, E(2, 30) = 
2.54, n < .05. Simple effects tests indicated that NAS DSM-IV withdrawal scores were 
not substantially elevated from O hour (M = 2.72, SD= 2.86) deprivation to 24 hour (M = 
3.5, SD= 2.42) and 48 hour (M = 3.22, SD= 2.26) during BACCOFF™ administration, E 
(2 30) = 1.55, ns. Significant withdrawal elevations were observed in conditions without 
BACCOFF™, E (2, 30) = 10.93, n < .001 as a function of time. As illustrated in Figure 2, 
follow-up analyses showed that withdrawal scores during 24 hour (M = 4.86, SD= 4.33) 
and 48 hour (M = 4.25, SD= 3.13) deprivation were significantly higher than O hour (M = 
2.34, SD= 2.91) deprivation. Comparisons ofBACCOFF™ X DIPSTOP™, E(l,15) = 
1.49, ns, DIPSTOP™ X Time, E (2, 30) = .25, ns, and BACCOFF™ X DIPSTOP™ X 
Time, E(2, 30) = .37, ns, were not significant. 
NAS Craving Scores 
A 2 BACCOFF™ (BACCOFF™ vs. no BACCOFF™) X 2 DIPS TOP™ (DIPSTOP™ 
vs. water) X 3 TIME (0-hr., 24-hr., and 48-hr.) repeated measures ANOV A was 
conducted on NAS Craving scores. The main effect for time showecl, significant increases 
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in craving symptoms, E (2, 30) = 7.17, R < .001. Tukey post-hoc tests exhibited lower 
craving scores during O hour (M = 1.00, SD = 1.22) deprivation compared to 24 hour (M 
= 1.61, SD= .94) and 48 hour deprivation (M = 1.86, SD= .95), as shown in Figure 3. 
BACCOFF™ and DIPSTOP™ main effects were not significant, Es (1, 15) = 1.33 and 
1.85, ns, respectively. 
There were no substantial interaction differences among BACCOFF™, DIPSTOP™, 
and Time comparisons. Interactions between BACCOFF™ X DIPSTOP™, E (1, 15) = 
1.48, ns, BACCOFF™ X Time, E (2, 30) = 1.65, ns, and DIPSTOP™ X Time, E (2, 30) = 
1.16, ns, were all nonsignificant. The three way interaction ofBACCOFF™ X 
DIP STOP™ X Time, E (2, 30) = · 1.30, ns, demonstrated no significant differences, as 
well. 
NAS Total Withdrawal Scores 
A 2 BACCOFF™ (BACCOFF™ vs. no BACCOFF™) X 2 DIPSTOP™ (DIPSTOP™ 
vs. water) X 3 TIME (0-hr., 24-hr., and 48-hr.) repeated measures ANOVA was 
conducted on the NAS total withdrawal scores. No significant main effect differences for 
BACCOFF™ and DIPSTOP™ were found, Es(l, 15) = 1.86 and 1.12, ns, respectively. 
Similar to Craving scores, Total withdrawal scores appear to significantly increase across 
time, E (2, 30) = 6.92, n < .001. Post-hoc tests showed that O hour (M = 5.49, SD= 
4.85) deprivation evinced significantly lower withdrawal scores compared to 24 hour (M = 
8.10, SD= 4.97) and 48 hour (M = 8.14, SD= 5.46) deprivation withdrawal scores. 
Time main effect results are shown in Figure 4. 
Significant interaction differences were not observed with total withdrawal scores. 
Consistent with Craving and DSM-IV scores, no significant results were observed with 
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BACCOFF™ X DIPSTOP™, E (1, 15) = .53, ns, BACCOFF™ X Time, E (2, 30) = 1.49, 
ns, and DIPSTOP™ X Time, E (2, 30) = .05, ns, interactions. The BACCOFF™ X 
DIPSTOP™ X Time interaction also demonstrated no substantial differences, E (2, 30) = 
.16, ns. 
BDI Scores 
A 2 BACCOFF™ (BACCOFF™ vs. no BACCOFF™) X 2 DIP STOP™ (DIPSTOP™ 
vs. water) X 3 TIME (0-hr., 24-hr., and 48-hr.) repeated measures ANOVA was 
conducted on the Beck depression scores. There were no significant BDI score findings. 
BACCOFF™, DIPSTOP™, and Time main effects were not significantly different, Es(l, 
15) = .88, .54, and 1.35, ns. Furthermore, BACCOFF™ X DIPSTOP™, E (1, 15) = .87, 
ns, BACCOFF™ X Time, E (2, 30) = 1.19, ns, and DIPSTOP™ X Time, E (2, 30) = .17, 
ns, comparisons showed no significant results. Moreover, no substantial.differences were 
observed among the BACCOFF™, DIPSTOP™, and Time interaction, E (2, 30) = .04, ns. 
STAI-State Scores 
A 2 BACCOFF™ (BACCOFF™ vs. no BACCOFF™) X 2 DIPSTOP™ (DIPSTOP™ 
vs. water) X 3 TIME (0-hr., 24-hr., and 48-hr.) repeated measures ANOVA was 
conducted on the STAI-State scores. Main effects for BACCOFF™, E (1, 15) = .04, ns, 
DIPSTOP™, E (1, 15) = .10, ns, and Time, E (2, 30) = 1.95, ns, did not significantly 
produce differences. Equally negligible were the BACCOFF™ X DIPSTOP™, E (1, 15) 
= .60, ns, BACCOFF™ X Time, E (2, 30) = .55, ns, and DIPSTOP™ X Time, E (2, 30) = 
.02, ns. The BACCOFF™ X DIPS TOP™ X Time interaction demonstrated no significant 
effects as well, E (2, 30) = .27, ns. 
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Discussion 
BACCOFF™ Administration 
The results partially supported the hypothesis that a variety of symptoms associated 
with smokeless tobacco 48-hour withdrawal would substantial reduce during 
BACCOFF™ administration. This study demonstrated that the withdrawal symptoms 
delineated in DSM-IV nicotine withdrawal criteria were suppressed across 48-hour 
deprivation as participants used the herbal substitute, BACCOFF™. This effect was not 
observed in conditions without BACCOFF™. When smokeless tobacco users were not 
given BACCOFF™, they endorsed significant more DSM-IV criteria withdrawal 
symptoms during 24 hour and 48-hour deprivation compared with a pre-quit baseline. 
Smokeless tobacco user's total withdrawal symptoms, craving, depression levels, 
and/or state anxiety levels showed no effects during BACCOFF™ administration. These 
results may reflect inherent differences between diagnosable symptoms versus general 
withdrawal patterns. Research has consistently documented nicotine withdrawal effects 
encompassing the dependent variables used in this study (Hughes & Hatsukami, 1986). It 
has also been suggested that DSM-IV withdrawal criteria may have stronger effects on 
smokeless tobacco users compared with other signs and symptoms of nicotine withdrawal 
(McChargue & Collins, 1998). Our data may help us better understand the relationship 
between DSM-IV nicotine withdrawal criteria and smokeless tobacco dependence. One 
possible explanation is that psychological components (e.g., topographical conditioning) 
may significantly contribute to the development of withdrawal symptoms associated with 
DSM-IV criteria while other withdrawal symptoms may be more pharmacologically based. 
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Dose-response limitations associated with the administration of the liquid drops may have 
also confounded these results. 
DIPSTOP™ Administration 
The hypothesis that smokeless tobacco 48-hour withdrawal would reduce during 
DIPSTOP™ administration was not supported by the results. Smokeless tobacco users' 
DSM-IV criteria withdrawal, craving, total withdrawal, depression levels, and anxiety 
levels were not influenced by DIPSTOP™ administration. Previous research examining 
lobeline (the primary ingredient in DIPSTOP™) effects on cigarette smokers' withdrawal 
symptoms has documented substantial reduction in withdrawal symptoms as the 
cumulative dosage oflobeline increased (Schneider et al., 1996). Given that lobeline 
appears to be more effective with increasing amounts, our data may reflect the lack of 
adequate dosing. Although dosing rates were found to be comparable with pre-
established dosing rates, participants controlled the amount of lobeline administered 
during each dose. Thus, the lack of standardized dosing may have influenced our results. 
Expectancy Effects 
The water condition was used to control expectancy effects related to DIPSTOP™ 
administration. There was no indication of a placebo response resulting from water 
administration. A placebp response would have been implicated if withdrawal symptoms 
reduced during the administration of water. These results would have suggested that 
participants were influenced by the possible expectancy that they were receiving an active 
substance that controls withdrawal symptoms. Our results did not show such an effect. 
Withdrawal symptoms substantially increased during water administration. 
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Instructions given during the administration of each product further contributed to the 
control of expectancy effects. Participants were told that they might or may not receive a 
substance that would help during deprivation. Anecdotally, participants consistently 
reported their uncertainty about the water condition containing an active substance during 
the debriefing. 
Although though participants reported an expectation that the DIPSTOP™ condition 
contain an active substance that may have helped with withdrawal, effects caused by these 
expectation could not be determined due to the lack of adequate dosing and significant 
results. The present study' s methodology would have been strengthened with lobeline 
administration by tablets and a placebo sugar pill. 
BACCOFF™ administration was more susceptible to expectancy effects. The product 
characteristics ( e.g., similar tin, taste, and form of administration) and lack of a placebo 
allows for potential expectancy effects. Although it is possible that the significant findings 
associated with BACCOFF™ administration may have been influenced by expectancies, 
the probability is low. If expectancy effects influenced BACCOFF™ administration, it is 
feasible to think that the results would not have been circumscribed to DSM-IV 
withdrawal symptoms. Other withdrawal patterns would have been equally affected. 
Therefore, disparate withdrawal findings during BACCOFF™ administration reduce the 
probability of expectancy effects. 
Effects of Time 
As smokeless users were deprived of nicotine use for 48 hours, their reported 
withdrawal symptoms appeared to increase over time. Previous withdrawal research has 
demonstrated that signs and symptoms of withdrawal are elevated in smokeless tobacco 
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users during deprivation (Hatsukami et al., 1987; Keenan et al., 1989, McChargue & 
Collins, 1998). Consistent with this research, participant's DSM-IV criteria withdrawal, 
craving, and total withdrawal substantially increased during 24 hour and 48 hour 
deprivation compared to baseline. This evidence suggests that 48-hour deprivation was an 
adequate amount of time to evidence withdrawal patterns. 
The depression and anxiety measures, however, were not affected by deprivation. 
These negligible results may reflect differences in severity and/or response patterns of 
smokeless tobacco users compared with smokers. It is well established that severe 
depression and anxiety problems are associated with cigarette smokers (Breslau, Kilbey & 
Andreski, 1991; Kendler et al., 1993). These symptoms are exacerbated during 
deprivation, especially with nicotine dependent individuals who have a history of major 
depression and/or anxiety disorders (Hall, Munoz & Reus, 1996; Hall et al., 1996). 
Current research examining smokeless tobacco users' withdrawal patterns has not 
thoroughly examined the relationship among depression, anxiety, and smokeless tobacco 
dependence. It is feasible to postulate that our nonsignificant findings may reflect affective 
constructs that do not influence smokeless tobacco withdrawal symptoms or may play a 
minimal role in the elicited withdrawal patterns. 
Conclusions 
Behavioral economics theory suggests that a substance's reinforcing properties control 
drug related behaviors as the individual interacts with the environment through their 
efforts to obtain the substance. This study sought to suspend smokeless tobacco behavior 
to elicit negative reinforcing properties (e.g., withdrawal) by prohibiting its use. The 
simultaneous introduction of two substitutable positive reinforcers that would mimic 
reinforcing and conditioned properties of smokeless tobacco were employed to evaluate 
the effects of deprivation. More specifically, smokeless tobacco withdrawal signs and 
symptoms were used to index these effects. If smokeless tobacco withdrawal did not 
significantly elevate from deprivation during product administration, substitutable 
reinforcers successfully influenced the course of negative reinforcing properties that 
typically prompt drug-seeking behaviors. 
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Overall, this study provided some promising effects of substitutable reinforcers and 
extended our understanding of smokeless tobacco dependence related to withdrawal. 
Supporting evidence found that withdrawal symptoms consistent with DSM-IV criteria 
were suppressed during the administration ofBACCOFF™, a nicotine-free herbal mixture. 
This effect was consistent with the concept that conditioned topographical features play an 
important role in maintaining smokeless tobacco behavior. 
Despite the promising effects found during BACCOFF™ administration, reduced 
smokeless tobacco withdrawal symptoms were not evidenced during DIP STOP™ 
administration, a nicotinic agonist. This substance's ineffectiveness further illustrates the 
importance of conditioned topographical features. Historically, researchers have posited 
that the primary determinant of withdrawal symptoms was the physiological removal of 
nicotine from the system (Hatsukami, Hughes & Pickens, 1985; Shiffinan, 1979). 
Withdrawal reduction without pharmacological adjuncts suggests that the physiological 
determinant of withdrawal may not be primary variable to consider during smokeless 
tobacco cessation. These findings implicate the possibility that conditioned reinforcers 
may override the physiological effects of withdrawal as nicotine dissipates from the 
system. 
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DSM-IV withdrawal symptoms' differential reduction observed during BACCOFF™ 
administration also suggests that these withdrawal symptoms are more amenable to 
smokeless tobacco reinforcing properties than craving and other symptoms not associated 
with DSM-IV. This study provided evidence that DSM-IV withdrawal, craving, and total 
withdrawal increased over time as a function of deprivation. BACCOFF™ 
administration's inability to control craving and total withdrawal symptoms experienced by 
smokeless tobacco users may suggest that these symptoms are more prone to 
physiologically based determinants. Furthermore, the lack of depressive and anxiety 
symptoms may suggest that smokeless tobacco users do not respond similarly to these 
symptoms compared to cigarette smokers. An alternative explanation is that the 
depression and anxiety measures did not accurately capture smokeless tobacco users 
expression of anxiety and depressive symptoms. 
Limitations 
The lack of a placebo for BACCOFF™ is the most significant limitation of this study. 
Although participants were instructed that the administered products might not help with 
withdrawal, a BACCOFF™ placebo would have further decreased the potential of 
expectancy effects. It cannot be definitely stated that the BACCOFF™ effects found in 
this study were caused by product administration only. It is feasible that the reduced 
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withdrawal symptoms may be a function of an expectation that BACCOFF™ would help 
alleviate withdrawal symptoms. 
The duration and frequency ofDIPSTOP™ administration may have been limited as 
well. A previous lobeline study found significant results as a function of the increased 
cumulative frequency, duration, and amount of the substance (Schneider et al., 1996). 
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Thus, there may be a critical period of adaptation to an individuals system before lobeline 
becomes an effective substitute. Furthermore, participants reported that the DIPSTOP™ 
product contained an unpleasant smell and taste. This potentially aversive component may 
have negatively affected the products potential. Moreover, the participant and not the 
researcher controlled the quantity of administered DIPSTOP™. Controlling the dose 
amount enhances the ability to quantify the substance's effect. 
The sole modality of measurement was collected through verbal report. This 
represents another limitation to the study. Multimodal assessment may have been more 
sensitive to smokeless tobacco withdrawal. Lang (1968) postulated that individuals 
express affective states through three systems: behavioral, cognitive, and physiological. 
This affective expression varies across individuals. For example, a smokeless user may 
experience the affective component of withdrawal (e.g., irritability) more physiologically 
compared with cognition and behavioral indices. This disparate response style may reflect 
minimized self-reported items with elevated muscle tension and increase heart rate. 
Although irritability may not have been identified through self-report measures in this 
example, a physiological assessment may have suggested an irritable state. Lang's theory 
is known as the bioinformational model of emotions. Theoretically, this approach may 
have evidenced physiological effects of DIPS TOP™ that could not be detected by verbal 
report measures. 
The NAS measure lacked reliability and validity data, which represented another limit 
to this study. Although the NAS has been shown to been sensitive enough to detect 
withdrawal differences in other studies (McChargue & Collins, 1998), it is unclear 
whether this measure reliably tests the construct of withdrawal. For instance, there may 
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be floor effects as a result of the measure's 4-point rating system. The standardization of 
this scale is needed to reduce the possibility of introducing error as an artifact from the 
assessment measures. 
Order effects must be considered as a possible limitation as well. The Latin square 
design directly manipulates the order of the conditions, which reduces randomization. 
This approach reduces the probability of order effects, but does not eradicate it. In 
addition, the statistical analyses testing for order effects significantly reduced the 
probability that the results were influenced by the order of presentation. 
The sample size of 16 participants may be too small to detect significant differences. 
Pre- and post-power analyses were conducted to assess the change in power from the use 
of previous effect sizes compared with the actual effect size. Possible reduction in power 
from pre- to post-analysis may limit our ability to draw conclusions from this study. The 
results of the power analyses indicated that power did not change from pre- to post-
analysis. These findings suggest that the sample size was adequate to identify significant 
differences. 
Finally, participants could have used smokeless tobacco during deprivation without the 
researcher's knowledge. COa levels are not produced by smokeless tobacco usage and 
budget limitations prevented the saliva samples from being analyzed. Therefore, these 
measures were employed to increase compliance and not used to detect smokeless tobacco 
consumption during deprivation. Although a deprivation compliance check at the end of 
the study identified that participants accurately documented their compliance during the 
protocol, retrospective reporting is inherently limited. Thus, cotinine analyses from the 
collected saliva samples would have been more exact. 
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Clinical Implications and Future Directions 
Smokeless tobacco treatment research has utilized pharmacological adjuncts, including 
nicotine-free adjuncts, as a component of treatment (Sinusas & Coroso, 1993; Stevens et 
al., 1995). However, these studies have only documented abstinent rates following 
treatment. This study illustrated the role nicotine-free adjuncts may play in treatment 
protocols. Our results showed that pharmacological substitutes that mimic reinforcing and 
conditioned properties are important in reducing withdrawal symptoms during abstinence. 
Treatment programs should emphasize components that will influence multiple reinforcing 
and conditioned properties, while controlling for a variety of withdrawal symptoms that 
may be elicited from different systems (psychological vs. physiological). 
The components of this study are relatively new in smokeless tobacco withdrawal 
research and have not been thoroughly examined. Future research should attempt to 
replicate the BACCOFfTM findings and explore a different duration of lobeline 
administration. It is also suggested that future research should utilize a less aversive and 
more controlled lobeline product, such as a tablet. Furthermore, a placebo for the 
BACCOFF™ product would strengthen our ability to draw definitive conclusions about 
the observed withdrawal effects. Moreover, the implementation ofBACCOFF™ and 
lobeline in a formal treatment protocol is needed to further elucidate the effectiveness of 
these substances. 
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Appendix A 
RESEARCH QUESTIONNAIRE 
Please Print Clearly (All information will remain confidential) 
Age __ Phone: ( ) ______ _ 
Best Time to Call 
-----
Sex M I F Psychology Instructor: 
-----
Section#: 
----
1. Do you have any medical conditions (for example, heart problems)? Yes No If yes, 
what type ________ _ 
2. Do you currently use tobacco products? (Circle one): 
Smoker Smokeless Tobacco User Both Don't use 
(IF YOU DO NOT USE TOBACCO, DO NOT COMPLETE THE REST OF TlilS FORM) 
3. Approximately how many times do you use smokeless tobacco or smoke a cigarette 
per day? (Circle One) 
Smokers: Less than 10 11-15 16-20 21-25 more than 25 
Smokeless: 1 2 3 4 5 more than 5 
4. How long have you smoked or used smokeless tobacco? 
Smokers ___ mnths I yrs Smokeless __ mnths I yrs 
5. Have you ever tried to quit before? (Circle One) 
Smoking: Yes No Smokeless: Yes No Both: Yes No 
6. If yes for #5, when was the last time you tried? MoNr ___ _ 
7. Have you substituted one form of tobacco use for another? Yes No 
8. Are you currently trying to quit smoking/smokeless tobacco or cut down? 
Smoking: Yes No Smokeless: Yes No 
AppendixB 
NAS (Page 1) 
CO I Subject #: SMT __ _ Week 1 2 3 4 Day, 1 2 3 Date: 
Directions: Please rate (circle) the degree to which each of the following descriptive 
words applies to you AT THIS MOMENT. 
At this Moment, I ... None Mild Moderate Severe 
1. Craving to smoke and/or chew/dip 0 1 2 3 
2. Feeling irritable 0 1 2 3 
3. Feeling anxious 0 1 2 3 
4. Having difficulty concentrating 0 1 2 3 
5. Feeling restless 0 1 2 3 
6. Experiencing a headache 0 1 2 3 
7. Feeling drowsy 0 1 2 3 
8. Experiencing stomach pains and/or nausea 0 1 2 3 
9. Feeling tired/fatigued 0 1 2 3 
10. Feeling impatient 0 1 2 3 
11. Feeling hungry 0 1 2 3 
12. Feeling down/depressed 0 1 2 3 
13. Feeling angry 0 1 2 3 
14. Feeling frustrated 0 1 2 3 
15. Did you have trouble sleeping last night? Yes No 
Heart Rate: (beats per 60secs) 
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Appendix B(Continued) 
NAS (Page 2) 
Subject #: SMT Study: SMT-03 Week: 1 2 3 4 Day: 1 2 3 
Directions: Please rate (circle) the degree to which each of the following descriptive 
words applies to you IN GENERAL. 
None Mild Moderate Severe 
In General, I have been ... 
1. Craving to smoke and/or chew/dip 0 1 2 3 
2. Feeling irritable 0 1 2 3 
3. Feeling anxious 0 1 2 3 
4. Having difficulty concentrating 0 1 2 3 
5. Feeling restless 0 1 2 3 
6. Experiencing a headache 0 1 2 3 
7. Feeling drowsy 0 1 2 3 
8. Experiencing stomach pains 
and/ or nausea 0 1 2 3 
9. Feeling tired/fatigued 0 1 2 3 
10. Feeling impatient 0 1 2 3 
11. Feeling hungry 0 1 2 3 
12. Feeling down/depressed 0 1 2 3 
13. Feeling angry 0 1 2 3 
14. Feeling frustrated 0 1 2 3 
15. Did you have trouble sleeping last night? Yes No 
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Appendix C 
LATIN SQUARE OF CONDITIONS 
Subject# 1st Week 2°d Week 3rd Week 4th week 
01 BXW DIP STOP ONLY BXD WATER 
ONLY 
02 DIPSTOP ONLY BXD WATER ONLY BXW 
03 BXD WATER ONLY BXW DIPS TO 
PONLY 
04 WATER ONLY BXW DIPS TOP ONLY BXD 
05 BXW DIPS TOP ONLY BXD WATER 
ONLY 
06 DIPS TOP ONLY BXD WATER ONLY BXW 
07 BXD WATER ONLY BXW DIPS TO 
PONLY 
08 WATER ONLY BXW DIPSTOP ONLY BXD 
09 BXW DIPSTOP ONLY BXD WATER 
ONLY 
10 DIPSTOP ONLY BXD WATER ONLY BXW 
11 BXD WATER ONLY BXW DIPS TO 
PONLY 
12 WATER ONLY BXW DIPS TOP ONLY BXD 
13 BXW DIP STOP ONLY BXD WATER 
ONLY 
14 DIPS TOP ONLY BXD WATER ONLY BXW 
15 BXD WATER ONLY BXW DIPS TO 
PONLY 
16 WATER ONLY BXW DIP STOP ONLY BXD 
Note. B X W = BACCOFF x Water, B X D = BACCOFF x DIPSTOP 
0 Hour Assessment 
24 Hour Assessment 
48 Hour Assessment 
AppendixD 
Experimental Procedure 
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Informed Consent (Initial Assessment Only) 
Smokeless Tobacco Questionnaire (Initial Assessment Only) 
10 Minute Smokeless Use 
Salivary Samples and Carbon Monoxide Levels 
Questionnaires: BDI, STAI, NAS 
Product Administration 
Frequency of Product Use Recorded 
Salivary Sample and Carbon Monoxide Levels 
Questionnaires: BDI, ST AI, NAS 
Frequency of Product Use Recorded 
Salivary Sample and Carbon Monoxide Levels 
Questionnaires: BDI, ST AI, NAS 
Debriefing 
Enter into lottery 
(Final Assessment Only) 
(Final Assessment Only) 
Subject# ___ _ Week# 
Day# __ _ 
BACCOFF (Yes or No) 
Drops 
Day# __ _ 
BACCOFF (Yes or No) 
Drops 
Day# __ _ 
BACCOFF (Yes or No) 
Drops 
AppendixE 
Frequency of Product Use] 
----
# of times used 
# of times used 
# of times used 
# of times used 
# of times used 
# of times used 
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AppendixF 
PARTICIPANT DEBRIEFING SHEET 
Purpose of the study 
The present study was designed to document the effects of DipstopTM (herbal 
nicotine agonist) and BACCOFFTM (herbal mixture) on withdrawal symptoms 
during smokeless tobacco deprivation. In recent years, smokeless tobacco sales and 
consumption have increased, especially adolescent and young adult consumption, 
compared to other tobacco products. There have been few studies, however, examining 
components of smokeless tobacco dependence, such as withdrawal patterns, and the 
effectiveness of psychopharmacological adjuncts with this population. This paucity of 
research necessitates systematic exploration in this area. 
Lobeline (main ingredient in Dipstop™) reliably mimics nicotinic effects in human 
and animal studies. Theoretically, lobeline administration should help prevent significant 
withdrawal symptoms during tobacco deprivation. Previous research, however, has been 
unable to demonstrate significant reductions in smoking behavior as a result of lobeline. 
To date, research has not provided empirical evidence documenting lobeline effects on 
withdrawal patterns with cigarette smokers or smokeless users. Furthermore, it has been 
speculated that the ineffective results in smoking behavior are a function of disparate 
absorption rates between lobeline and cigarettes. Research has shown that the absorption 
of lobeline is a gradual process which plateaus with continuous use. This pattern appears 
to be closer to smokeless tobacco rates. Thus, lobeline may be more appropriately 
employed with smokeless users rather than cigarette smokers. 
BACCOFF™ research has primarily been anecdotal. This evidence suggests that 
BACCOFF™ may be an effective substitute for smokeless tobacco. There has only been 
one empirical study using BACCOFF™. This study examined cue reactivity related to 
smokeless tobacco. Researchers found that BACCOFF™ produced similar olfactory, 
tactile, and taste responses to smokeless tobacco. These findings suggest that 
BACCOFF™ may help control behavioral components (e.g., reinforcement stimuli) of 
nicotine dependence. 
Deception 
Participants were told that carbon monoxide levels would detect nicotine in the 
system. However, research has shown that COa levels are good indicators for smokers 
only. The CO monitor measures the level of carbon monoxide in the lungs. Smokeless 
tobacco does not produce carbon monoxide in the lungs. Thus, this measure was used to 
facilitate abstinence compliance. 
Saliva samples were not used to analyze cotinine levels. The samples were stored 
in a freezer until the participant completed the study. After completion, samples were 
discarded. This measure was used to increase abstinence compliance as well. 
The purpose of these measures were to create an environment that appeared easy 
to detect nicotine use during abstinent days. Remaining nicotine-free for two consecutive 
days each week for four weeks was vital to the experiments success. Using nicotine 
during the abstinent days (Tues. and Weds.) may influence the participants level of 
reported withdrawal and skew our results. Therefore, it was important to facilitate 
compliance. 
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Table 1 
Frequency of Demographic Information from Smokeless Tobacco Dependence 
Questionnaire Items among Smokeless Tobacco Participants 
SMDTQitem Responses Smokeless Tobacco Participant 
Preferred Smokeless Tobacco Skoal 9 
Copenhagen 7 
Tins per Week <2 0 
>2and<4 5 
>4 11 
Hours Dipping per Day < 14.5 4 
> 14.5 and< 15.5 7 
> 15.5 5 
Difficulty Refraining from Use Yes 9 
No 7 
Table 2 
Mean Alveolar Carbon Monoxide Levels Arcoss Time and Condition 
Condition 
BACCOFF™ X Water 
BACCOFF™ X DIPSTOP 
DIPSTOP™ Only 
Water Only 
Baseline 
1.6 (1.3) 
1.3 (1.0) 
1.4 (1.1) 
1.6 (0.7) 
24 Hour 
1.9 (1.3) 
1.8 (1.1} 
1.1 (0.8) 
1.0 (.73) 
48 Hour 
1.4 (1.2) 
1.9 (1.2) 
1.3 (0.9) 
1.4 (1.0) 
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Table 3 
Deprived Smokeless Tobacco Users' Mean BACCOFF™ Administration Across 
Condition 
Condition 
BACCOFF™ X DIPSTOP™ 
BACCOFF™ X Water 
DIPSTOP™ Only 
Water Only 
24 hours 
4.4 (2.5) 
4.6 (3.7) 
48 hours 
5.4 (3.7) 
5.2 (2.3) 
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Table 4 
Deprived Smokeless Tobacco Users' Mean Liquid Drop Administration Across 
Condition 
Condition 
BACCOFF™ X DIPSTOP™ 
BACCOFF™ X Water 
DIPSTOP™ Only 
Water Only 
24 hours 
3.1 (I.I) 
2.9 (1.0) 
3.0 (0.7) 
2.9 (0.9) 
48 hours 
3.2 (1.2) 
3.6 (1.0) 
3.5 (1.0) 
3.6 (1.2) 
73 
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Figure Captions 
Figure 1. Mean NAS DSM-IV withdrawal rating across time for smokeless tobacco users 
(N = 16). Significant withdrawal differences as a function of time are denoted with an 
asterisk. 
Figure 2. Mean DSM-IV withdrawal ratings for BACCOFF™ vs. No BACCOFF™ 
differences across time. Differences were noted in the No BACCOFF™ treatment. 
Figure 3. Mean NAS Craving ratings across time for smokeless tobacco users (N = 16). 
Significant craving differences as a function of time are denoted with an asterisk. 
Figure 4. Mean NAS Total withdrawal ratings across time for smokeless tobacco users 
(N = 16). Significant withdrawal differences as a function of time are denoted with an 
asterisk. 
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